You just read:

Wize Pharma Receives IRB Approval of Phase IV Study Protocol for LO2A in Symptomatic Treatment of Dry Eye Syndrome in Patients With Sjögren's Syndrome

News provided by

Wize Pharma, Inc.

Feb 20, 2018, 01:30 ET